Elzasonan citrate is a selective 5-HT1B and 5-HT1D receptor antagonist for the treatment of depression. By preferentially blocking 5-HT1B and 5-HT1D autoreceptors, Elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects. References: Kamel A, Colizza K, Obach RS. In vitro metabolism of the 5-hydroxytryptamine1B receptor antagonist elzasonan. Xenobiotica. 2013 Apr;43(4):368-78. doi: 10.3109/00498254.2012.723150. Epub 2012 Oct 3. PubMed PMID: 23030680.

纯度：≥98%

CAS：361343-20-6